LL-37
Also known as Cathelicidin · hCAP18 fragment
New
Reconstitution & dosing guide
5 mg vial — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only5mg x 10 vials
LL37 · Not in current stock
$50 / vial
Prices per vial · Research use only · Not medical advice.
Human antimicrobial peptide with immune and wound-related roles; experimental and potentially pro-inflammatory.
How to picture it
LL-37 is a human antimicrobial peptide that can disrupt microbe membranes and also act as an alarm/modulator for immune cells. Picture a dual-purpose security tool: direct antimicrobial activity plus immune and repair coordination at barrier tissues. Research frames it as security plus after-action signaling — not only targeting threats, but participating in how tissue responds afterward.
Research focus & benefits
- Antimicrobial peptide research
- Innate immune signaling studies
- Wound and barrier-tissue interface science
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
LL-37 is the active fragment of human cathelicidin. It kills microbes, modulates immune responses, and participates in wound responses. Therapeutic interest is real, but systemic use can be a double-edged sword (inflammation, possible autoimmune concerns).
Mechanism
Disrupts microbial membranes; chemotactic and immunomodulatory signaling; influences autophagy and wound environments.
Research uses
- Antimicrobial research
- Chronic wound studies
- Autoimmunity and inflammatory disease research
- Respiratory infection research
Research dosing notes
Not a casual immune peptide; pro-inflammatory potential means medical caution.
Half-life / kinetics
Short
Common research routes
Reported considerations
- Inflammation
- Injection pain
- Theoretical autoimmunity flares
- Hemolytic potential at high local levels
Contraindications / cautions
- Active autoimmune disease without specialist
- Pregnancy
- Sepsis self-treatment
Common research stacks
- Often wrongly stacked in complex infection protocols — seek infectious disease care
Legal / access note
Research use; not approved as a general antimicrobial drug for self-injection.